Ratings by Lucid Capital Markets (Elemer Piros)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/8/2026 | Tvardi Therapeutics Inc | TVRD | New Coverage | Buy (N/A) |
1.91 (1.87) |
-2.09% | Details | |
| 9/1/2026 | Nuvectis Pharma | NVCT | New Coverage | Buy (N/A) |
22.73 (23.99) |
5.54% | Details | |
| 6/15/2026 | Adial Pharmaceuticals Inc | ADIL | New Coverage | Buy (N/A) |
2.98 (4.90) |
64.43% | Details | |
| 5/13/2026 | NRX Pharma | NXRP | New Coverage | Buy (N/A) |
0.00 () |
0% | Details | |
| 4/27/2026 | XOMA Royalty Corp | XOMA | Downgrade | Neutral (Buy) |
37.90 (40.17) |
5.99% | Details | |
| 4/20/2026 | Passage Bio Inc. | PASG | Downgrade | Neutral (Buy) |
11.67 (5.00) |
-57.16% | Details | |
| 4/15/2026 | NervGen Pharma Corp | NGEN | New Coverage | Buy (N/A) |
4.19 (2.19) |
-47.73% | Details | |
| 3/11/2026 | INmune Bio Inc. | INMB | Upgrade | Buy (Neutral) |
1.28 (2.22) |
73.44% | Details | |
| 1/30/2026 | Quince Therapeutics Inc. | QNCX | Downgrade | Sell (Buy) |
0.27 (29.55) |
10844.44% | Details | |
| 12/17/2025 | VistaGen Therapeutics | VTGN | Downgrade | Neutral (Buy) |
4.36 (0.24) |
-94.5% | Details | |
| 12/9/2025 | XOMA, Ltd. | XOMA | New Coverage | Buy (N/A) |
30.49 (37.90) |
24.3% | Details | |
| 11/24/2025 | Passage Bio Inc. | PASG | New Coverage | Buy (N/A) |
7.74 (11.67) |
50.78% | Details | |
| 11/12/2025 | Unicycive Therapeutics | UNCY | Maintain | Buy (N/A) |
|
Details | ||
| 10/21/2025 | Neuphoria Therapeutics Inc. | NEUP | Downgrade | Neutral (Buy) |
15.40 (3.73) |
-75.78% | Details | |
| 10/6/2025 | Cassava Sciences | SAVA | New Coverage | Buy (N/A) |
3.63 (2.38) |
-34.44% | Details | |
| 10/6/2025 | Cassava Sciences | SAVA | New Coverage | Buy (N/A) |
3.63 (3.63) |
0% | Details | |
| 9/30/2025 | Ocugen, Inc. | OCGN | New Coverage | Buy (N/A) |
1.45 (1.02) |
-29.66% | Details | |
| 9/22/2025 | Coya Therapeutics | COYA | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2025 | Ovid Therapeutics Inc | OVID | New Coverage | Buy (N/A) |
0.55 (2.69) |
389.09% | Details | |
| 7/31/2025 | OKYO Pharma Ltd. | OKYO | New Coverage | Buy (N/A) |
2.51 (1.40) |
-44.22% | Details | |
| 7/22/2025 | Tiziana Life Sciences | TLSA | New Coverage | Buy (N/A) |
1.62 (0.96) |
-40.74% | Details | |
| 7/1/2025 | INmune Bio Inc. | INMB | Downgrade | Neutral (Buy) |
5.33 (1.28) |
-75.98% | Details | |
| 6/6/2025 | Cybin Inc. | CYBN | New Coverage | Buy (N/A) |
8.82 (8.28) |
-6.12% | Details | |
| 6/6/2025 | atai Life Sciences N.V | ATAI | New Coverage | Buy (N/A) |
2.48 (7.35) |
196.37% | Details | |
| 6/4/2025 | Unicycive Therapeutics | UNCY | New Coverage | Buy (N/A) |
0.76 (5.29) |
596.05% | Details | |
| 6/4/2025 | INmune Bio Inc. | INMB | New Coverage | Buy (N/A) |
7.27 (5.33) |
-26.69% | Details |
